智通财经APP讯，轩竹生物-B(02575)公布，于 2025年11月14日，董事会经考虑及批准实施H股全流通的建议，即将公司六名股东持有的357,245,794股公司未上市股份转换为公司H股(占公司于本公告日期已发行股份总数约68.9733%)。待取得所有相关批准(包括向中国证监会存档)并遵守所有适用法律、法规及规则后，357,245,794股未上市股份将转换为H股，而公司亦将向联交所申请批准该等H股于联交所主板上市及买卖。
于本公告日期，公司尚未向中国证监会申请H股全流通。
智通财经APP讯，轩竹生物-B(02575)公布，于 2025年11月14日，董事会经考虑及批准实施H股全流通的建议，即将公司六名股东持有的357,245,794股公司未上市股份转换为公司H股(占公司于本公告日期已发行股份总数约68.9733%)。待取得所有相关批准(包括向中国证监会存档)并遵守所有适用法律、法规及规则后，357,245,794股未上市股份将转换为H股，而公司亦将向联交所申请批准该等H股于联交所主板上市及买卖。
于本公告日期，公司尚未向中国证监会申请H股全流通。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.